Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza to make cancer drug for Denmark’s Allarity

by Rick Mullin
October 1, 2021 | A version of this story appeared in Volume 99, Issue 36

 

The structure of dovitinib.

The pharmaceutical services firm Lonza has agreed to manufacture dovitinib, an investigational pan-tyrosine kinase inhibitor for metastatic renal cell carcinoma, for the Danish biotech firm Allarity Therapeutics. Under the contract, active ingredient production and particle reduction by micronization will take place at Lonza’s facility in Visp, Switzerland. Lonza will make the finished drug in Tampa, Florida. Novartis licensed dovitinib to Allarity in 2018 after disappointing trials as a kidney cancer drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.